RB1 and metastatic neoplasm: Patients with RB1 alterations in the primary tumor had a significantly shorter overall survival (OS) (median OS from metastatic disease 2.32 years; 95% CI: 1.82–3.84; P = 0.006) (Table 3 and Supplemental Figure 4).